apraglutide vs teduglutide (Gattex)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Short Bowel Syndrome

Shared mechanism: GLP-2 receptor · full Short Bowel Syndrome pipeline

apraglutide

Developed by Ironwood Pharmaceuticals

Phase 3 in Short Bowel Syndromepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT05018286 (registry estimate)

No aligned efficacy figure on record for this race.

teduglutide (Gattex)

Marketed by Takeda Pharmaceutical Company

Approved in Short Bowel Syndromepeptide
Partial signal

NCT00798967 · Phase 3 · completed

The trial was randomized, quadruple-blind, and placebo-controlled, with 43 participants per group, and its clinical primary endpoint was met (p=0.002). However, the available record does not report the power or sample-size calculation needed to verify that the study was adequately powered, so the evidence is graded moderate rather than strong.

Next expected readout: January 2027 · NCT07400783 (registry estimate)

Reported efficacy

Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants (unclear)

Result source: NCT02682381

Results for Short Bowel Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

apraglutide: no structured comparison results are available for Short Bowel Syndrome.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

teduglutide (Gattex)
Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects NCT00798967 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
A Graded Response Score in Parenteral Nutrition (PN) Reduction (6 months): Placebo — 0 (No Response): 15 participants; 1: 0 participants; 2: 1 participants; 4: 0 participants; 5 (No longer need PN): 0 participants | Teduglutide 0.05 mg/kg/d — 0 (No Response): 19 participants; 1: 6 participants; 2: 6 participants; 4: 2 participants; 5 (No longer need PN): 2 participants | Teduglutide 0.1 mg/kg/d — 0 (No Response): 24 participants; 1: 2 participants; 2: 4 participants; 4: 2 participants; 5 (No longer need PN): 0 participants NCT00081458 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants NCT02682381 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apraglutide's landscape · teduglutide (Gattex)'s landscape